Gene therapy for inherited retinal degeneration in which expression of a mutant allele has a gain-of-function effect on photoreceptor cells is likely to depend on efficient silencing of the mutated allele. Peripherin-2 (Prph2, also known as peripherin/RDS) is an abundantly expressed photoreceptorspecific gene. In humans, gain-of-function mutations in PRPH2 result in both autosomal dominant retinitis pigmentosa and dominant maculopathies. Gene-silencing strategies for these conditions include RNA interference by short hairpin RNAs (shRNAs). Recent evidence suggests that microRNA (miRNA)-based hairpins may offer a safer and more effective alternative. In this study, we used for the first time a virally transferred miRNA-based hairpin to silence Prph2 in the murine retina.
Introduction
Inherited retinal disorders are a major cause of blindness affecting 41.5 million individuals worldwide. [1] [2] [3] [4] [5] Dominantly inherited retinal degenerations are a subcategory of retinopathies that lead to progressive loss of photoreceptors caused either by haploinsufficiency because of loss-of-function mutations, the deleterious effect of dominant negative mutations or by the toxic effect of gain-of-function mutations. To date, mutations in 45 genes have been identified as a cause of dominant retinal degenerations, including conditions such as autosomal dominant retinitis pigmentosa (adRP) and dominant maculopathies (Retnet Database, 2009). Peripherin-2 (Prph2) is a highly expressed photoreceptor-specific gene in which mutations often lead to dominantly inherited retinal disorders. The gene product, PRPH2, is a 32 kDa structural membrane glycoprotein localized in the photoreceptor outer segments in which it forms multisubunit components with its homolog ROM-1. It is an essential component in outer segment morphogenesis, a vital daily process of photoreceptors to replenish the outer segment tips that are being phagocytosed by the retinal pigment epithelium. 6 To date, over 90 different PRPH2 mutations that cause retinopathies have been identified. 7 Dominant retinopathies caused by mutations in PRPH2 are relatively common, with PRPH2 mutations involved in up to 25% of central retinal dystrophies, such as a variety of macular dystrophies, cone-rod dystrophies and central areolar choroidal dystrophies, as well as 9% of adRP. [7] [8] [9] [10] [11] Even though individuals with dominant PRPH2 mutations often show inter-and intra-familial variation, most observe visual disturbances by middle age.
Gene replacement therapy is a promising approach for the specific treatment of recessively inherited disorders caused by loss-of-function mutations and a means to deliver neuroprotective proteins in retinal degenerations generically. 5, [12] [13] [14] However, therapies for dominant retinopathies, in which expression of a mutant allele has a dominant negative effect on photoreceptor cell function or survival, are likely to depend on efficient silencing of the mutated allele. Ribozyme technology and RNAi have been used to target specifically mRNA from mutated genes involved in adRP, and RNAi in particular can result in efficient gene silencing. [15] [16] [17] [18] [19] [20] Local delivery of silencing short hairpin RNA (shRNA) cassettes using viral vectors such as AAV can result in sustained knockdown of the mutated gene, often leading to prolonged improvement of the adRP phenotype. [21] [22] [23] [24] [25] [26] Although vector-mediated RNAi offers a potentially powerful approach to the treatment of dominant disease, the molecular kinetics of the RNAi pathway have yet to be fully defined and the success in selecting a potent RNAi modulator still depends on a 'hit-or-miss' approach in which a range of RNAi molecules that span the coding sequence of the gene of interest are screened to identify the most efficient target area. Although such screening is appropriate where there is more than one potential target region, this method in unsuitable where there is no alternative, for instance in targeting a point mutation for allele-specific silencing. In addition to the fact that there are no effective solutions to date for the enhancement of an shRNA's efficiency when choice of target area is limited, there is also a potential for significant off-target adverse effects. 27, 28 Solutions for these problems in RNAi design may be found in studying endogenous microRNAs (miRNAs).
The discovery of endogenous miRNAs led to the development of 'miRNA mimetics' in which the design of miRNAs is used to accommodate RNAi target sequences to increase their silencing efficiency and, most importantly, reduce toxicity caused by shRNA-dependent saturation of the endogenous pathway. Indeed, miRNA-based design of RNAi hairpins has been shown to both increase efficiency and reduce toxicity possibly as a result of their intracellular processing. [29] [30] [31] [32] In this study, we evaluated the efficiency of an miRNA-based shRNA-targeting Prph2 (miRDS6) in vivo using AAV2/8 viruses. The efficiency of miRDS6 in silencing Prph2 was also compared with a conventionally designed hairpin (shRDS6). After subretinal delivery of AVV2/8 pseudotyped vectors, histological analysis showed that the miRNA-based shRNA robustly and consistently silenced Prph2 expression both in vitro and in vivo. This study provides the first assessment of a virally delivered miRNA in the retina for the silencing of an abundantly expressed photoreceptor gene and shows the potential of miRNA mimetics in RNAi applications for the treatment of dominantly inherited retinal degeneration.
Results
For the development of a potent Prph2-silencing hairpin, three target sequences (siRDS4, siRDS5 and siRDS6) were selected from an online design website (http:// www.Dharmacon.com), together with a non-targeting control (siCON), and their efficacy was assessed in vitro. We engineered a 293T-HEK cell line that stably expresses Prph2 for hairpin evaluation. HEK cells were infected with a lentiviral vector expressing Prph2 from a spleen focus-forming virus promoter at a limiting MOI (that is o1), and single cells were propagated to obtain a number of stable cell lines expressing Prph2 from a single integrated expression cassette. The cell lines were characterized and Prph2 expression was quantified by immunoblotting. We selected one cell line (293T/ wtRDS + ) in which Prph2 expression was fivefold higher than endogenous b-actin expression (Figure 1a ). This cell line was used for assessing the three siRNAs. Their efficacy in Prph2 knockdown was assessed by immunobloting and siRDS6 was selected for subsequent experiments as the most potent Prph2-targeting siRNA (Figure 1b) .
Evasion of silencing by a hairpin can be achieved through 'silent mutagenesis' within the target area 22, 26, 33 and such an engineered cDNA could be used for future applications of suppression and replacement, which is the process of gene supplementation with an engineered cDNA that is not silenced by the target hairpin after all endogenous expression has been abolished. Hence, the first three triplets within the first eight nucleotides or 'seed region' of RDS6 were altered to abolish shRNA:mRNA binding while retaining the wildtype amino-acid sequence (Figure 2 ). The mutated Prph2 cDNA was named mutRDS and a stably expressing cell line (293T/mutRDS + ) was constructed in a similar manner as that used to generate 293T/wtRDS + . Having established a potent target area for Prph2 knockdown that was evaluated using siRNA transfections (siRDS6), an miRNA-based hairpin with the same target area was designed. The miRNA template used was miR-30a 34 and the hairpin was named miRDS6. Similarly, the nontargeting control sequence (siCON) was also redesigned based on miR-30a (miRCON). In addition to miRCON and miRDS6, a conventional shRNA-targeting Prph2 at the same target area as miRDS6 was designed (shRDS6) to be tested alongside miRDS6 in vitro and in vivo ( Figure 3 ).
The two Prph2-targeting hairpin cassettes (shRDS6 and miRDS6) and the non-targeting control (miRCON) were cloned into an AAV vector backbone that also drives the expression of red fluorescent protein (RFP) through a chicken b-actin promoter. Before the production of recombinant AAV2/8 (AAV2/8) particles, all three plasmids were tested in vitro on both 293T/wtRDS + and 293T/mutRDS + cell lines. After transfection, the cells Site-directed PCR mutagenesis was performed in mutRDS to alter nucleotides within the region targeted by RDS6. Three nucleotides (in bold italics) were altered using the degeneracy of the genetic code to retain codon characteristics. Both codon series encode for the amino-acids Tyrosine-Serine-Tyrosine. The relative abundances for each tRNA in the mouse are indicated and suggest that protein translation would not be hampered by codon substitution.
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were sorted by FACS to select for RFP + cells, total RNA was extracted and Prph2 levels were determined by quantitative real-time PCR (qRT-PCR) ( Figure 4 ). No silencing was observed in any of the 293T/mutRDS + transfections indicating that the silencing capacity of shRDS6 or miRDS6 was abolished because of the threepoint mutations inserted within the 'seed region' of the target area. In contrast, both shRDS6 and miRDS6 knocked down Prph2 in 293T/wtRDS + cells to 54 and 17% of the untransfected levels, respectively. Transfection of the miRCON hairpin did not result in Prph2 silencing in either 293T/wtRDS + or 293T/mutRDS + in comparison with untransfected control.
All three plasmids were used to produce AAV2/8 particles that were titre matched before being subretinally injected into adult wild-type mice (n ¼ 4). Three weeks after injection, retinae were dissociated and RFP + photoreceptors were sorted by FACS. Total RNA was extracted and endogenous Prph2 levels were assessed by qRT-PCR ( Figure 5 ). Within the transduced photoreceptors, shRDS6 silenced Prph2 to 80% of the miRCON levels, whereas miRDS6 showed a knockdown to around 17% of the miRCON levels. To investigate the impact of endogenous Prph2 knockdown by each of the targeting constructs, histological analysis was performed 3 weeks after subretinal injection in an additional cohort of adult wild-type mice (n ¼ 4) (Figure 6 ). After a single subretinal injection for each of the AAV2/8 vectors, RFP reporter gene expression indicated that the majority of photoreceptor cells were transduced in the area of detachment (Figure 6a ). Prph2 immunolabeling was performed on serial sections and the level of immunostaining in transduced areas was assessed. Although there was strong Prph2 immunostaining within a uniform and tightly packed outer segment layer after AAV2/ 8.RFP.miRCON injection (Figure 6b ), staining levels were reduced in eyes that had received either AAV2/ 8.RFP.shRDS6 or AAV2/8.RFP.miRDS6 (Figures 6c and  d) . Although shRDS6-mediated silencing did not greatly reduce Prph2 staining, outer segments disks were loosely packed leading to voids within the treated area ( Figure  6c ). On the other hand, miRDS6-mediated silencing significantly reduced Prph2 immunolabeling leading to almost complete loss of the outer segment layer within the treated area (Figure 6d ). For Prph2 immunolabeling in untreated retinae, see Supplementary Figure 1 .
To assess further the impact of Prph2 silencing, ultrastructural analysis was performed 5 weeks after vector administration (n ¼ 4) (Figure 7 ). After subretinal injection of AAV2/8.RFP.miRCON, the retinal architecture and outer segments seemed normal as visualized by light (Figures 7a and b) and electron microscopy ( Figure 7c ). After injection of AAV2/8.RFP.shRDS6, outer segments were present (Figures 7d and e) , but seemed Figure 3 Sequence and molecular structure of shRDS6 and miRDS6 hairpins. The RNA hairpin structures for shRDS6 and miRDS6 are depicted. The wild-type sequence of the endogenous miR30a hairpin that was used as a template is also shown. The RDS6 target area is depicted in italics. * ¼ G:U wobble pairing. Figure 4 In vitro expression levels of Prph2 after transfection of RNAi cassettes. Relative expression levels of wtRDS and mutRDS in 293T cells (adjusted to b-actin levels) were analysed using quantitative real-time PCR (qRT-PCR) after transfection of plasmids expressing miRCON, shRDS6 and miRDS6 hairpins. No silencing was observed for mutRDS in any of the conditions, whereas wtRDS was only silenced by shRDS6 and miRDS6 constructs to 53.98 ± 18.6 and 17.19 ± 12.2% of the untransfected levels, respectively. *Po0.05, **Po0.001 (Student's t-test; n ¼ 4). 
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A Georgiadis et al to be shorter and less well organized (Figure 7f ). However, after administration of the vector expressing the miRNA, AAV2/8.RFP.miRDS6, there was an even greater impact on outer segment morphology (Figures 7g  and h ). The outer segments were significantly reduced in length and highly disorganized (Figure 7i ), resembling those seen in the Prph2 +/Rd2 mouse (rds heterozygote). 35 Although the impact of Prph2 silencing on outer segment morphology was obvious at 3 weeks after injection ( Figure 6 ), after 5 weeks, the outer nuclear layer thickness also seemed to be reduced, particularly in eyes that had received the miRDS6-expressing viruses. The number of photoreceptor nuclei was quantified within treated areas of procedured eyes and age-matched uninjected controls (Figure 8 ). No significant differences were found between the number of photoreceptor nuclei in uninjected eyes and those that had received AAV2/ 8.RFP.miRCON. However, shRDS6-mediated silencing resulted in a 5% reduction in the number of photoreceptors (Po0.05) and miRDS6-mediated silencing resulted in a 46% reduction (Po0.001).
Discussion
For the treatment of dominant disorders, there is a need for a potent, non-toxic silencing vehicle to abolish the expression of the mutated gene with or without allelic discrimination. With the advancement of RNAi toward clinical application during the last few years, concerns have been raised over non-specific toxic effects of hairpin administration in vivo that can cause liver toxicity and fatality in mice. 27 The reasons for such effects observed after hairpin administration are not fully understood and might be tissue specific or gene specific. Despite these concerns, progress has been made in successfully downregulating mutated genes experimentally in the retina and brain of mice. 21, 22, 26, 36, 37 Some studies have recently concentrated on miRNAs and their use as a template to accommodate an RNAi target. [29] [30] [31] [32] 34 When comparing shRNA versus miRNAmediated silencing, the latter seems to confer more efficient silencing with less toxic effects. McBride and coworkers 30 showed that dose-independent toxicity 
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A Georgiadis et al caused by some shRNAs in the mouse striatum could be avoided by incorporating the target sequence into an miRNA-based template. 30 In an elaboration of that study, Boudreau and coworkers 32 showed that shRNAs disrupt miRNA biogenesis causing neurotoxicity in mouse cerebella. The concept of minimizing toxicity by entering the natural pathway of RNAi at an earlier point is of considerable interest for potential clinical application, and considering their increased potency, 31 miRNA approaches are likely to attract increasing attention.
Here, we used the miRNA template of the murine miR-30a molecule, one of the most studied miRNAs, to accommodate a Prph2-targeting hairpin. The target sequence of an siRNA that efficiently silenced Prph2 (siRDS6) in vitro was cloned into an AAV vector backbone using the miR30-based design (miRDS6) and tested against the non-targeting control (miRCON) and a conventional hairpin (shRDS6). In the 293T/RDS + cell line, miRDS6 robustly knocked down Prph2 to 17% of control levels, thereby surpassing in efficiency the conventional shRDS6 by almost threefold. The efficiency of Prph2 knockdown observed in vitro by shRDS6 and miRDS6 were mirrored in vivo 3 and 5 weeks after AAV2/8-mediated delivery. In addition, we assessed how the degeneracy of the genetic code could be used to generate a Prph2 cDNA (mutRDS) that is not silenced by the miRDS6 hairpin. The mutRDS transgene could be used in suppression and replacement approaches to treat models with gain-of-function mutations, because of the haploinsufficiency that may rise after preferential silencing of the mutant allele. However, the use of endogenous Prph2 regulatory sequences and promoter should be considered to ensure efficient levels of expression.
It is worth noting that the efficiency of miRDS6 was very consistent between in vitro and in vivo experiments (Prph2 knockdown to 17% of control levels), whereas shRDS6-mediated silencing varied in vitro and in vivo (50-80% of control levels). Whether this consistency is directly caused by the miRNA-based design, remains to be determined. More studies could cast light on the adaptability of hairpin design in different experimental contexts.
In this study, we show for the first time that an miRNA-based design can efficiently be used in AAV2/ 8-mediated silencing of an abundantly expressed photoreceptor-specific gene (Prph2) in vitro and in vivo in miRDS6 (g-i) . Injection of AAV2/8.RFP.miRCON resulted in normal retinal ultrastructure with healthy outer segment morphology. AAV2/8.RFP.shRDS6 injection resulted in shorter and less well-organized outer segments throughout the treated area. After AAV2/8.RFP.miRDS6 injection, the outer segments were substantially reduced in length and highly disorganized. ONL, outer nuclear layer; IS, inner segments; OS, outer segments; RPE, retinal pigment epithelium; Mv, microvilli. Size bar, 20 mm (semithin panel) and 2 mm (ultrathin panel).
A Georgiadis et al murine retinae. The sequence of miR30a has been used earlier in vitro 31,34 and here we report that the enhancement of silencing is also observed in vivo in the mouse retina, successfully knocking down Prph2, the second most abundant retinal protein. These results further support the use of miRNA-based shRNA design to increase a hairpin's efficiency, as this may be required in allelic discrimination approaches for the treatment of gain-of-function dominant disorders. Although we cannot conclude that miRNA-based design will de facto increase the efficiency of any conventionally designed shRNA, this should now be tested. Further studies could identify other efficient miRNA molecules to be used as a template 31 in conjunction with polymerase II RNA promoters. Suitable candidates should also be tested using RNA microarray analysis for lack of off targeting and lack of saturation of the endogenous miRNA pathway by confirming the levels of the miRNA's natural target. Such efficient platforms delivered by vectors such as AAV2/8 that mediate very efficient transduction of photoreceptors could further advance the development of treatments for dominant retinopathies.
Materials and methods

Constructs and vector production
The targeting constructs for Prph2 were created by subcloning the target hairpins (shRDS6 or miRDS6) into the mU6pro plasmid. In the mu6pro vector, the target hairpins are placed downstream of a U6 promoter to form an RNAi-expression cassette. The RNAi cassettes were subsequently excised and cloned into the AAV pD10.RFP backbone. The RDS6 targets the Prph2 sequence 5 0 -CTACAGCTATGACCATCA-3 0 (position nt 911-928. NM_008938). The RDS6 target area is conserved between murine and human Prph2 orthologs. The shRDS6 hairpin was designed using a standard shRNA motif of sense-loop-antisense in which the loop consisted of six nucleotides. The miRDS6 hairpin was designed based on the miR-30a miRNA sequence as described earlier 34 ( Figure 3 ). An additional non-targeting control hairpin consisting of a scrambled RDS6 sequence was also designed based on the miR-30a design (miRCON). The resulting vectors were named pD10.RFP.shRDS6, pD10.RFP.miRDS6 and pD10.RFP.miRCON, respectively (the intermediate mu6pro-based constructs were likewise named mu6shRDS6, mu6miRDS6 and mu6miR-CON). The sequence of mutRDS differs from wtRDS at three nucleotide positions within the RDS6 target area (Figure 2) , while encoding the same amino acids and retaining relative tRNA abundance. Production of rAAV2/8 particles was carried out as described earlier 38 and the resulting AAV preparations (AAV2/ 8.RFP.shRDS6, AAV2/8.RFP.miRDS6 and AAV2/8.RFP. miRCON) were titre matched before use.
Subretinal injections
Six to eight-week-old female wild-type C57BL/6 mice were used for this study (n ¼ 36). All animals were cared for in accordance with the UK Home Office regulations. Mice were anaesthetized by intraperitoneal injections of Dormitor (1 mg ml -1 , Pfizer Pharmaceuticals, UK) and ketamine (100 mg ml -1 , Fort Dodge Animal Health, UK) mixed with sterile water in the ratio 5:3:42. Surgery was performed under direct retinoscopy through an operating microscope as described elsewhere. 39 A total of 2 ml of virus suspension (10 9 viral genomes) were injected to produce a bullous retinal detachment in the superior hemisphere of each eye.
Sectioning and imaging
Mice were killed at 3 and 5 weeks after injection and the eyes were immediately orientated with a nasal stitch. The eyes were fixed in 3% glutaraldehyde and 1% paraformaldehyde buffered to pH 7.4 with 0.07 M sodium cacodylate-HCl buffer, the cornea and lens were removed and the eye cups were processed as described earlier. 40 Semithin sections (0.7 mm) were cut using a Leica ultracut S microtome fitted with a diamond knife (Diatome histoknife). Sections were stained with 1% toluidine blue stain and slides were mounted with DPX after the sections had dried. Photoreceptor nuclei counts were performed on images of 32 semithin sections per treatment group, all taken within the treated area around the optic nerve head. The images were taken in a standardized manner (as in Figures 7b, e and h ). Error bars indicate standard deviation of the mean. Ultrathin sections (70 nm) were cut using a Leica ultracut S microtome fitted with a diamond knife for ultrathin sections (Diatome histoknife for ultrathin sections). Sections were taken from treated areas of retinae and collected onto grids. Sections were stained with uranyl acetate for 10 min and lead citrate for 7 min and then washed with dH 2 O. After the sections had dried, they were analyzed by electron microscopy (JEOL 1010 TEM). For cryosections, eyes were retrieved and immediately immersed in 1% paraformaldehyde for 2 h. After fixation, the eyes were embedded and frozen in optimum cutting temperature medium and 12 mm thick sections were cut using a Bright cryostat. Confocal imaging was performed with a 3-laser ZEISS LSM 510UV Confocal Imager and its software was used to capture images. 
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Generation of Prph2-expressing stable cell lines
Human embryonic kidney cells (HEK; 293T) were infected with a lentivirus driving the expression of murine Prph2 (either mutRDS or wtRDS) through a spleen focus-forming virus promoter, at a limiting MOI (that is o1). Single cells were propagated and the clonal populations were tested for Prph2 expression by western blotting.
Western blotting and qRT-PCR
For western blotting, total cell extracts were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (12%) and transferred to nitrocellulose for immunoblotting. Imaging was performed by incubation with a specific primary antibody followed by a horseradish peroxidase-conjugated secondary antibody. For Prph2 imaging, a primary rabbit-polyclonal antibody was used (kind gift from Gabriel Travis, UCLA); b-actin was used as a control. The nitrocellulose membrane was subsequently stripped and a primary rabbit-polyclonal antibody toward b-actin was used (Sigma, Dorset, UK).
For real-time PCR, cultured cells or dissociated retinae were harvested and sorted by FACS, selecting for RFP + cell populations. RNA was extracted using RNeasy Mini Kit (Qiagen, West Sussex, UK) and cDNA preparation was performed using QuantiTect Reverse Transcription Kit (Qiagen). Relative quantification by real-time PCR of Prph2 against endogenous b-actin-expression levels were measured using the following sets of primers: murine 
Immunohistochemistry
Cryosections were air dried for 10 min and blocked for 1 h with a TBS-T solution containing 3% BSA, Triton-X (0.5%) and 5% serum of the species within which the 21 antibody was raised in. The 11 antibody directed against Prph2 (kind gift from Gabriel Travis, UCLA) was added and sections were incubated overnight at 4 1C. After washing with TBS-T, sections were incubated with the respective 21 antibody in blocking solution for 2 h at room temperature. The sections were counterstained with DAPI (Sigma) and mounted with mounting medium (DAKO, Ely, UK).
